Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later.

ABSTRACT:

Objectives

We compared the ability of molecular biomarkers for Alzheimer disease (AD), including amyloid imaging and CSF biomarkers (Aβ42, tau, ptau181, tau/Aβ42, ptau181/Aβ42), to predict time to incident cognitive impairment among cognitively normal adults aged 45 to 88 years and followed for up to 7.5 years.

Methods

Longitudinal data from Knight Alzheimer's Disease Research Center participants (N = 201) followed for a mean of 3.70 years (SD = 1.46 years) were used. Participants with amyloid imaging and CSF collection within 1 year of a clinical assessment indicating normal cognition were eligible. Cox proportional hazards models tested whether the individual biomarkers were related to time to incident cognitive impairment. "Expanded" models were developed using the biomar

SUBMITTER: Roe CM 

PROVIDER: S-EPMC3719431 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature